James Harrison, CEO of Archimica, declared: "We are very pleased to have this opportunity to apply our expertise to the manufacturing of naproxcinod and are excited by the clear potential of this innovative product. We look forward to continuing our work with the NicOx team, and leveraging our manufacturing experience to support their timely and successful launch of naproxcinod."
NicOx is developing naproxcinod in phase 3 clinical studies, which are designed to demonstrate that it is safe, well tolerated and effective for treating the signs and symptoms of osteoarthritis, in addition to having no detrimental effect on blood pressure, in contrast to existing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). The final pivotal phase 3 trials are ongoing (the 302 and 303 studies) and the filing of a New Drug Application (NDA) for naproxcinod is projected for mid-2009.
Archimica is a privately held pharmaceutical fine chemicals company
owned by TowerBrook Capital Partners and Aisling Capital Partners.
Archimica combines first-class chemical manufacturing assets, technologies
and process development with a history of pharmaceutical commercialization
that stretches back over 40 years. With respect to new manufacturing
projects, Archimica's strategy is focused on phase 2 and phase 3 clinical
trial manufacturing opportunities for New Chemical Entities (NCEs) and this
partnership with NicOx on naproxcinod is an important ex
|SOURCE NicOx S.A.|
Copyright©2008 PR Newswire.
All rights reserved